Ignite Creation Date:
2024-05-05 @ 11:48 AM
Last Modification Date:
2024-10-26 @ 9:13 AM
Study NCT ID:
NCT00138671
Status:
TERMINATED
Last Update Posted:
2010-02-02
First Post:
2005-08-26
Brief Title:
A One Year Clinical Trial Assessing the Usefulness and Safety of Inhaled Insulin in Diabetics With COPD
Sponsor:
Pfizer
Organization:
Pfizer
Study Overview
Official Title:
Efficacy and Safety of Inhaled Human Insulin Exubera Compared With Subcutaneous Human Insulin in the Therapy of Adult Subjects With Type 1 or Type 2 Diabetes Mellitus and Chronic Obstructive Pulmonary Disease A One-Year Multicenter Randomized Outpatient Open-Label Parallel-Group Comparative Trial
Status:
TERMINATED
Status Verified Date:
2009-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
See termination reason in detailed description
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
A One Year Clinical Trial Assessing the Usefulness and Safety of Inhaled Insulin in Diabetics with Chronic Obstructive Pulmonary Disease
Detailed Description:
Pfizer announced in October 2007 that it would stop marketing Exubera At that time recruitment for study A2171030 was placed on hold Nektar the company from which Pfizer licensed Exubera announced on April 9 2008 that it had stopped its search for a new marketing partner Accordingly there will be no commercial availability of Exubera As a result study A2171030 was terminated on June 17 2008 Neither safety nor efficacy reasons were the cause of the study termination
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None